APOE4 moderates the association between cerebral small vessel disease and cortical tau accumulation in midlife

Liliana Espinoza, Matthew R. Scott, Alexa Beiser, Andy Banh, Vinu Philip, Saptaparni Ghosh, Emma G. Thibault, Pauline Maillard, Charles DeCarli, Georges El Fakhri, Keith A. Johnson, Sudha Seshadri, Claudia L. SatizábalAlzheimer 2024 · DOI

TL;DR

This study reveals that in cognitively healthy middle-aged adults, the presence of the APOE-ε4 gene variant significantly amplifies the link between early signs of cerebral small vessel disease (measured by "free water" in MRI) and tau protein accumulation in specific brain regions. This suggests that APOE-ε4 may accelerate the early pathological processes of Alzheimer's disease by exacerbating the impact of vascular damage on tau pathology.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is characterized by the accumulation of tau protein tangles in the brain. Recent research has pointed to a potential link between tau pathology and cerebral small vessel disease (CSVD), a common condition that affects the brain's blood vessels. It's hypothesized that CSVD might contribute to tau accumulation, and this interplay might be particularly important in the early stages of AD, even before cognitive decline is apparent. However, the precise nature of this relationship, especially in midlife individuals who are not yet demented, remains unclear. Furthermore, the APOE-ε4 gene is a known risk factor for AD, and understanding how it influences the CSVD-tau connection is crucial for unraveling early AD pathogenesis. This paper aims to investigate the association between a marker of CSVD and tau accumulation in specific brain regions in middle-aged, cognitively healthy individuals, and to explore whether the APOE-ε4 genotype modifies this association.

Methods

The researchers utilized data from 281 cognitively healthy participants from the Framingham Heart Study. They employed two key neuroimaging techniques:

  • Brain MRI: This was used to measure "free water" (FW) in the brain. Elevated FW is considered an early indicator of CSVD, reflecting increased interstitial fluid due to compromised blood-brain barrier function and tissue damage.
  • Tau PET Imaging: This technique allowed for the quantification of tau protein accumulation in specific cortical regions, namely the rhinal, entorhinal, and inferotemporal cortices. These regions are known to be affected early in the tau pathology spread in AD.

The study used linear regression models to assess the relationship between FW and regional tau accumulation. They conducted two models: Model 1 adjusted for basic demographic and imaging-related factors (age, sex, camera type, and time between scans). Model 2 further adjusted for a comprehensive set of cardiovascular risk factors, including systolic blood pressure, antihypertensive medication use, type 2 diabetes, body mass index, smoking status, and prevalent cardiovascular disease. A key aspect of their analysis was exploring the interaction term between FW and APOE-ε4 carriership to determine if the APOE-ε4 genotype moderated the association.

Datasets

The study utilized data from the Third Generation Cohort of the Framingham Heart Study. This is an existing, well-established longitudinal aging study. No new datasets were introduced or created for this research.

Key Insights and Ideas

  • CSVD and Tau: A Complex Relationship: The study found no direct, significant association between general markers of CSVD (free water) and tau accumulation across all participants. This suggests that the relationship might be more nuanced and dependent on other factors.
  • APOE-ε4 as a "Risk Multiplier": The most striking finding is that the APOE-ε4 genotype appears to act as a moderator. In individuals carrying the APOE-ε4 allele, signs of CSVD are significantly linked to increased tau accumulation in key brain regions. This suggests that vascular damage might have a more detrimental impact on tau pathology in APOE-ε4 carriers.
  • Early Stage Pathology: The investigation focused on cognitively healthy individuals, highlighting that these pathological processes (CSVD and tau accumulation) can occur and interact even before the onset of clinical symptoms of dementia. This is crucial for understanding the very early stages of AD development.
  • Region-Specific Effects: The interaction between CSVD and APOE-ε4 was most pronounced in the rhinal and entorhinal cortices, which are known to be among the first brain areas affected by tau pathology in AD.

Key Results

  • In fully adjusted models, there was a significant interaction between free water (FW) and APOE-ε4 genotype on tau accumulation in the rhinal (p=0.079) and entorhinal cortices (p=0.071). While these p-values are borderline, they suggest a trend towards significance.
  • Specifically among APOE-ε4 carriers, higher FW was significantly associated with increased rhinal tau levels (β=1.49, p=0.031).
  • A borderline significant association was also found between higher FW and increased entorhinal tau in APOE-ε4 carriers (β=1.25, p=0.061).
  • No significant associations between FW and tau were observed in individuals who did not carry the APOE-ε4 allele.

Limitations and Future Work

The authors acknowledge that replication studies in larger samples are needed to confirm these findings, particularly given the borderline significance of some interaction results. Future work could focus on:

  • Investigating this interaction in a larger and more diverse cohort to increase statistical power and generalizability.
  • Exploring other markers of CSVD and their interaction with APOE-ε4 on tau pathology.
  • Longitudinal studies to track the progression of both CSVD and tau accumulation and their relationship with cognitive decline in APOE-ε4 carriers.
  • Examining the underlying biological mechanisms by which APOE-ε4 might exacerbate the link between vascular damage and tau spread.

Summary updated

Abstract

Abstract Background Recent research suggests that soluble pathogenic tau accumulates in the brain microvasculature of patients with Alzheimer’s Disease (AD) and primary tauopathies, driving cerebrovascular impairments and further tau accumulation. However, little is known about the interplay of these processes before dementia onset. In the present study, we investigated the association between free water (FW), an early biomarker of cerebral small vessel disease, and tau accumulation in the rhinal, entorhinal, and inferotemporal cortices derived from PET imaging in middle‐aged adults. Additionally, given the known increased risk of AD among APOE‐ɛ4 carriers, we further explored the interaction between FW and APOE‐ɛ4 carriership on tau accumulation. Method We included 281 cognitively healthy participants (mean age 55±9 years, 49% male, 23% APOE‐ɛ4 carriers) from the Third Generation Cohort of the Framingham Heart Study who had undergone brain MRI and tau PET imaging. We used linear regression models to relate FW to regional tau, adjusting for potential confounders. Model 1 was adjusted for age, age 2 , sex, camera, and time interval between MRI and PET scans. Model 2 was additionally adjusted for cardiovascular risk factors (i.e. systolic blood pressure, antihypertensive medication use, type 2 diabetes, body mass index, smoking, and prevalent cardiovascular disease). Result Although we did not find a significant association between FW and regional tau, we observed significant interactions between FW and APOE‐ ɛ4 genotype on tau accumulation in the rhinal (p=0.079) and entorhinal cortices (p=0.071) in fully adjusted models (Table 1). Among APOE‐ɛ4 carriers, we found a significant association between higher FW and increased rhinal tau levels (β=1.49, p=0.031), and a borderline significant association between higher FW and increased entorhinal tau (β=1.25, p=0.061). No significant associations were observed in non‐APOE‐ɛ4 carriers. Conclusion Our findings suggest that the APOE‐ɛ4 genotype is a moderator in the association between cerebrovascular injury and tau accumulation in brain regions typically affected earlier in the pathological spreading of tau in AD. These findings may help further elucidate underlying early processes leading to tau propagation. Replication studies in larger samples are needed to confirm these findings.
BibTeX
@inproceedings{espinoza2024apoe,
  author = {Liliana Espinoza and Matthew R. Scott and Alexa Beiser and Andy Banh and Vinu Philip and Saptaparni Ghosh and Emma G. Thibault and Pauline Maillard and Charles DeCarli and Georges El Fakhri and Keith A. Johnson and Sudha Seshadri and Claudia L. Satizábal},
  title = {{APOE4 moderates the association between cerebral small vessel disease and cortical tau accumulation in midlife}},
  booktitle = {Alzheimer},
  year = {2024},
  doi = {10.1002/alz.091824},
}
Figure